"Recognition for domestic manufacturing of microfluid-based 메이저 바카라사이트 장난감 injectables and LNP manufacturing technology"
[by Jin, Yu Jeong] Inventage Lab announced on November 27 that it received a commendation from the Minister of Health and Welfare for its contribution to health industry promotion and commercialization of healthcare technology at the ‘2025 Healthcare Industry Performance Exchange Meeting.
The company clarified that the award recognized its contribution to reinforcing the competitiveness of the biohealth industry in Korea, driven by the development of 메이저 바카라사이트 장난감 injectables and messenger ribonucleic acid (mRNA) therapeutic production technology.
Inventage Lab has been developing long-acting injectable technology using its proprietary ‘IVL-DrugFluidic’ platform. This technology supports consistent drug release within the body and enables the design of long-acting injectables with efficacy sustained from one month up to a year, offering significant improvements in patient convenience.
Based on IVL-DrugFluidic, Inventage Lab has achieved milestones that include collaborations with global pharmaceutical companies, clinical trials, technology transfer agreements, and contract manufacturing (CMO) partnerships. The platform has also supported the company’s listing on the KOSDAQ market. Additionally, Inventage Lab has actively engaged in social contribution initiatives, including co-development efforts with the Korean Association Against Drug Abuse, in partnership with the National Assembly, aimed at developing treatments for opioid and alcohol dependence.
Furthermore, Inventage Lab has independently developed a lipid nanoparticle (LNP) manufacturing technology essential for messenger ribonucleic acid (mRNA) vaccines and gene therapy development. According to the company, the automated equipment ‘HANDYGENE,’ built on the ‘IVL-GeneFluidic’ platform, delivers more consistent particle quality and a more stable production process than foreign technologies and equipment. On this foundation, Inventage Lab has established a production line supporting automated, continuous manufacturing, thereby laying the groundwork for stable domestic LNP production.
Inventage Lab emphasized that its achievements have received external recognition through multiple awards granted to key members, including the Prime Minister’s Award received by CEO Kim Ju-hee, the Technologist Award from the Pharmaceutical Society of Korea, and the Presidential Citation awarded to Chief Technology Officer (CTO) Chon Chan-hee. "This Minister's Award is national recognition for our company's consistent R&D, commercialization, and social contribution activities. Next year will be the inaugural year of our global commercialization efforts, with the goal of growing into a competitive company in the global market," said Kim Ju-hee, CEO of Inventage Lab.
In parallel, 메이저 바카라사이트 장난감 Lab is advancing commercialization and technology transfer for its microfluidic-based drug delivery system (DDS) platform, encompassing long-acting injectables, LNP technology, subcutaneous (SC) formulation technology for biopharmaceuticals, and oral peptide formulation technology. The company recently obtained significant outcomes from a joint research project with the multinational pharmaceutical company Boehringer Ingelheim and entered into a joint R&D agreement for long-acting injectables covering additional peptide candidates, laying the foundation for global technology commercialization.